This is the response duration curve
This is the response duration curve and the median duration of response for the CR’s has not yet been met. There were only seven patients, but only three of them have relapsed. For the partial responses; there are a number of patients with partial responses who had very good partial responses, greater that 95% tumor shrinkage. Some of those patients probably simply had fibrous scar in an area that was still casting a shadow. But even in the partial responses some of these patients have had very durable responses. One point that I need to make, and may have been made also in some of the monoclonal antibody talks that you’ve had earlier, is that one of the initial thoughts was that with immunotherapy you could only expect to see shrinkage of very small tumors. That the immune system simply didn’t have enough oomph to it to cause regression of large tumors. In the experience with rituximab and certainly the experience with interleukin-2 has proven that simply not to be the case. Seems like the patients who are going to respond are going to respond almost regardless of the size of their tumor. Performance status is very important but with that caveat, that the patient has good performance status, the size of the tumor is not really a predictor of response.
Generic viagra online
On this slide, the number of patients who responded is plotted on the Y axis, and on the X axis is the tumor area in square centimeters. So the patients represented in this bar to the far right would have greater than 10×10 centimeter tumors because their total area was 100 square centimeters. This group would be greater than 7×7 and this would be greater than 5×5 centimeters. As you can see, if anything, there is a weighting of patients to this side of the curve. Clearly not all of these patients are simply patients with small one or two centimeter pulmonary nodules.
Generic Prilosec
So it seems that the patients who are going to respond to this treatment are going to respond and it’s very hard to predict in advance who is going to respond and who is not going to. And that’s important because this treatment, as approved by the FDA and is outlined in the package insert, is incredibly toxic and you cannot really give this treatment without being willing to make these patients extremely sick – if you are going to give it by the approved package insert. To do this you need to be in an institution that has a very good intensive care group and an intensive care group that is interested in managing these patients. Because the side effects of interleukin-2 really mimic those of septic shock. Septic shock being primarily manifested by cytokine production. It’s not surprising that treating patients with high doses of interleukin-2 would mimic that appearance. Almost all these patients will have hypertension. In many will be very significant, about three-quarters requiring pressor support. Mental status changes are common; 5% of the patients in this series developed grade IV mental status changes. That’s frank psychosis often requiring four-point restraints. Some of the patients became comatose, some of the patients developed respiratory failure requiring ventilatory support. And the patients who died from the treatment were patients who developed infections near the end of their treatment course. It’s easy to overlook these infections because the fever and the hypotension is something that you also get from the interleukin-2. But it’s in those patients who wind up dying from this high dose treatment. So this is not for the faint-of-heart, either by the patient or by the treating physician, and there are centers in the country who do this on a regular basis, and I think you really have to consider sending them to one of those centers unless you are planning to make this a major focus of your practice.